Serum resistin concentrations in children with Kawasaki disease

Inflammation Research

Volumn 59, Issue 11, 2010, Pages 915-920

  Nozue, Hiroki ^a   Imai, Hironori ^a   Saitoh, Hisako ^a   Aoki, Takeshi ^a   Ichikawa, Kunio ^a   Kamoda, Tomohiro ^b  

^a Tsukuba Medical   (Japan)

^b UNIVERSITY OF TSUKUBA   (Japan)

Author keywords

Body mass index; Kawasaki disease; MCP 1; Resistin

Indexed keywords

ACETYLSALICYLIC ACID; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; C REACTIVE PROTEIN; IMMUNOGLOBULIN; MONOCYTE CHEMOTACTIC PROTEIN 1; RESTIN;

ADIPOCYTE; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BODY MASS; BODY WEIGHT; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY ANEURYSM; DISEASE SEVERITY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HEMATOCRIT; HIGH RISK POPULATION; HUMAN; INFLAMMATION; JAPANESE; LEUKOCYTE COUNT; MACROPHAGE; MALE; MONOCYTE; MUCOCUTANEOUS LYMPH NODE SYNDROME; PRESCHOOL CHILD; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SINGLE DRUG DOSE; THROMBOCYTE COUNT;

CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; INFANT; JAPAN; MALE; MUCOCUTANEOUS LYMPH NODE SYNDROME; RESISTIN;

EID: 78651281622     PISSN: 10233830     EISSN: 1420908X     Source Type: Journal    
DOI: 10.1007/s00011-010-0202-8     Document Type: Article

References (45)

1. Steppan CM, Bailey ST, Bhat S, Brown EJ, Banerjee RR, Wright CM, et al. The hormone resistin links obesity to diabetes. Nature. 2001;409:307-12.
2. Silha JV, Krsek M, Skrha JV, Sucharda P, Nyomba BL, Murphy LJ. Plasma resistin, adiponectin and leptin levels in lean and obese subjects: correlations with insulin resistance. Eur J Endocrinol. 2003;149:331-5.
3. Janke J, Engeli S, Gorzelniak K, Luft FC, Sharma AM. Resistin gene expression in human adipocytes is not related to insulin resistance. Obes Res. 2002;10:1-5.
4. Patel L, Buckels AC, Kinghorn IJ, Murdock PR, Holbrook JD, Plumpton C, et al. Resistin is expressed in human macrophages and directly regulated by PPAR gamma activators. Biochem Biophys Res Commun. 2003;300:472-6.
5. Ukkola O. Resistin-a mediator of obesity-associated insulin resistance or an innocent bystander? Eur J Endocrinol. 2002;147:571-4.
6. Kawasaki T, Kosaki F, Okawa S, Shigematsu I, Yanagawa H. A new infantile acute febrile mucocutaneous lymph node syndrome (MCLS) prevailing in Japan. Pediatrics. 1974;54:271-6.
7. Kato H, Koike S, Yamamoto M, Ito Y, Yano E. Coronary aneurysms in infants and young children with acute febrile mucocutaneous lymph node syndrome. J Pediatr. 1975;86:892-8.
8. Furukawa S, Matsubara T, Jujoh K, Yone K, Sugawara T, Sasai K, et al. Peripheral blood monocyte/macrophages and serum tumor necrosis factor in Kawasaki disease. Clin Immunol Immunopathol. 1988;48:247-51.
9. Furukawa S, Matsubara T, Umezawa Y, Okumura K, Yabuta K. Serum levels of p60 soluble tumor necrosis factor receptor during acute Kawasaki disease. J Pediatr. 1994;124:721-5.
10. Matsubara T, Ichiyama T, Furukawa S. Immunological profile of peripheral blood lymphocytes and monocytes/macrophages in Kawasaki disease. Clin Exp Immunol. 2005;141:381-7.
11. Ichiyama T, Yoshitomi T, Nishikawa M, Fujiwara M, Matsubara T, Hayashi T, et al. NF-jB activation in peripheral blood monocytes/macrophages and T cells during acute Kawasaki disease. Clin Immunol. 2001;99:373-7.
12. Furukawa S, Matsubara T, Jujoh K, Sasai K, Nakachi S, Sugawara T, et al. Reduction of peripheral blood macrophages/monocytes in Kawasaki disease by intravenous gammaglobulin. Eur J Pediatr. 1990;150:43-7.
13. Ichiyama T, Ueno Y, Hasegawa M, Niimi A, Matsubara T, Furukawa S. Intravenous immunoglobulin inhibits NF-kappaB activation and affects Fc gamma receptor expression in monocytes/macrophages. Naunyn Schmiedebergs Arch Pharmacol. 2004;369:428-33.
14. Japan Kawasaki Disease Research Committee. Diagnostic guidelines of Kawasaki disease. 4th ed. Tokyo: Japan Kawasaki Disease Research Committee; 1984.
15. Harada K. Intravenous γ-globulin treatment in Kawasaki disease. Acta Paediatr Jpn. 1991;33:805-10.
16. Migita K, Maeda Y, Miyashita T, Kimura H, Nakamura M, Ishibashi H, et al. The serum levels of resistin in rheumatoid arthritis patients. Clin Exp Rheumatol. 2006;24:698-701.
17. Konrad A, Lehrke M, Schachinger V, Seibold F, Stark R, Ochsenkühn T, et al. Resistin is an inflammatory marker of inflammatory bowel disease in humans. Eur J Gastroenterol Hepatol. 2007;19:1070-4.
18. Larochelle J, Freiler J, Dice J, Hagan L. Plasma resistin levels in asthmatics as a marker of disease state. J Asthma. 2007;44:509-13.
19. Sundén-Cullberg J, Nyström T, Lee ML, Mullins GE, Tokics L, Andersson J, et al. Pronounced elevation of resistin correlates with severity of disease in severe sepsis and septic shock. Crit Care Med. 2007;35:1536-42.
20. Burns JC, Grodé MP. Kawasaki syndrome. Lancet. 2004;364:533-44.
21. Lang BA, Silverman ED, Laxer RM, Lau AS. Spontaneous tumor necrosis factor production in Kawasaki disease. J Pediatr. 1989;115:939-43.
22. Matsubara T, Furukawa S, Yabuta K. Serum levels of tumor necrosis factor, interleukin 2 receptor, and interferon gamma in Kawasaki disease involved coronary artery lesions. Clin Immunol Immunopathol. 1990;56:29-36.
23. Maury CPJ, Salo E, Pelkonen P. Circulating interleukin-1 in patients with Kawasaki disease. N Engl J Med. 1988;319:1670.
24. Ueno Y, Takano N, Kanegane H, Yokoi T, Yachie A, Miyawaki T, et al. The acute phase nature of interleukin 6: studied in Kawasaki disease and other febrile illness. Clin Exp Immunol. 1989;76:337-42.
25. Eberhard BA, Andersson U, Laxer RM, Rose R, Silverman ED. Evaluation of the cytokine response in Kawasaki disease. Pediatr Infect Dis J. 1995;14:199-203.
26. Asano T, Ogawa S. Expression of IL-8 in Kawasaki disease. Clin Exp Immunol. 2000;122:514-9.
27. Kaser S, Kaser A, Sandhofer A, Ebenbichler CF, Tilg H, Patsch JR. Resistin messenger-RNA expression is increased by proinflammatory cytokines in vitro. Biochem Biophys Res Commun. 2003;309:286-90.
28. Bokarewa M, Nagaev I, Dahlberg L, Smith U, Tarkowski A. Resistin, an adipokine with potent proinflammatory properties. J Immunol. 2005;174:5789-95.
29. Bo S, Gambino R, Pagani A, Guidi S, Gentile L, Cassader M, et al. Relationships between human serum resistin, inflammatory markers and insulin resistance. Int J Obes (Lond). 2005;29:1315-20.
30. Shetty GK, Economides PA, Horton ES, Mantzoros CS, Veves A. Circulating adiponectin and resistin levels in relation to metabolic factors, inflammatory markers, and vascular reactivity in diabetic patients and subjects at risk for diabetes. Diabetes Care. 2004;27:2450-7.
31. Al-Daghri N, Chetty R, McTernan PG, Al-Rubean K, Al-Attas O, Jones AF, et al. Serum resistin is associated with C-reactive protein and LDL cholesterol in type 2 diabetes, coronary artery disease in a Saudi population. Cardiovasc Diabetol. 2005;4:10.
32. Asano T, Ogawa S. Expression of monocyte chemoattractant protein-1 in Kawasaki disease: the anti-inflammatory effect of gamma globulin therapy. Scand J Immunol. 2000;51:98-103.
33. Terai M, Kohno Y, Namba M, Umemiya T, Niwa K, Nakajima H, et al. Class II major histocompatibility antigen expression on coronary arterial endothelium in a patient with Kawasaki disease. Hum Pathol. 1990;21:231-4.
34. Terai M, Jibiki T, Harada A, Terashima Y, Yasukawa K, Tateno S, et al. Dramatic decrease of circulating levels of monocyte chemoattractant protein-1 in Kawasaki disease after gamma globulin treatment. J Leukoc Biol. 1999;65:566-72.
35. Verma S, Li SH, Wang CH, Fedak PW, Li RK, Weisel RD, et al. Resistin promotes endothelial cell activation: further evidence of adipokine-endothelial interaction. Circulation. 2003;108:736-40.
36. Fu Y, Luo L, Luo N, Garvey WT. Proinflammatory cytokine production and insulin sensitivity regulated by overexpression of resistin in 3T3-L1 adipocytes. Nutr Metab (Lond). 2006;3:28.
37. Fehmann HC, Heyn J. Plasma resistin levels in patients with type 1 and type 2 diabetes mellitus and in healthy controls. Horm Metab Res. 2002;34:671-3.
38. Lee JH, Chan JL, Yiannakouris N, Kontogianni M, Estrada E, Seip R, et al. Circulating resistin levels are not associated with obesity or insulin resistance in humans and are not regulated by fasting or leptin administration: cross-sectional and interventional studies in normal, insulin-resistant, and diabetic subjects. J Clin Endocrinol Metab. 2003;88:4848-56.
39. McTernan PG, Fisher FM, Valsamakis G, Chetty R, Harte A, McTernan CL, et al. Resistin and type 2 diabetes: regulation of resistin expression by insulin and rosiglitazone and the effects of recombinant resistin on lipid and glucose metabolism in human differentiated adipocytes. J Clin Endocrinol Metab. 2003;88:6098-106.
40. Youn BS, Yu KY, Park HJ, Lee NS, Min SS, Youn MY, et al. Plasma resistin concentrations measured by enzyme-linked immunosorbent assay using a newly developed monoclonal antibody are elevated in individuals with type 2 diabetes mellitus. J Clin Endocrinol Metab. 2004;89:150-6.
41. Yannakoulia M, Yiannakouris N, Blüher S, Matalas AL, Klimis-Zacas D, Mantzoros CS. Body fat mass and macronutrient intake in relation to circulating soluble leptin receptor, free leptin index, adiponectin, and resistin concentrations in healthy humans. J Clin Endocrinol Metab. 2003;88:1730-6.
42. Fujinami A, Obayashi H, Ohta K, Ichimura T, Nishimura M, Matsui H, et al. Enzyme-linked immunosorbent assay for circulating human resistin: resistin concentrations in normal subjects and patients with type 2 diabetes. Clin Chim Acta. 2004;339:57-63.
43. Vozarova de Courten B, Degawa-Yamauchi M, Considine RV, Tataranni PA. High serum resistin is associated with an increase in adiposity but not a worsening of insulin resistance in Pima Indians. Diabetes. 2004;53:1279-84.
44. Gerber M, Boettner A, Seidel B, Lammert A, Bär J, Schuster E, et al. Serum resistin levels of obese and lean children and adolescents: biochemical analysis and clinical relevance. J Clin Endocrinol Metab. 2005;90:4503-9.
45. Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW Jr. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Investig. 2003;112:1796-808.